Table 2.
Summary of cost inputs associated with clinical inputs, 2018 U.S. Dollars
| Parameter | 2018 $US |
|---|---|
| BAT | $34,500 |
| Heart failure medications, annual (a) | |
| ACE/ARB (b) | $852.00 |
| Beta Blocker | $34.20 |
| Digitalis | $480.00 |
| Diuretics | $144.00 |
| ARNI | $6,109.44 |
| Ivabradine | $5,309.04 |
| MRA (c) | $503.76 |
| Other HF meds | $1,299.32 |
| CV non-HF hospitalization (d) | $6,731.68 |
| Heart failure hospitalizations | $6,293.13 |
| LVAD (e) | $186,954.96 |
| Heart transplant | $173,846.71 |
| BAT specific serious adverse events (f) | |
| Infections | $11,842.98 |
| Prolonged intubation (requiring overnight stay) | $2,527.66 |
| Abx allergic reaction (BAT implanted at later date) | $4,824.03 |
| Heart failure exacerbation | $2,527.66 |
| Acute respiratory failure (consequence of anesthesia) | $10,565.57 |
| Pneumonia resulting in intubation | $5,775.02 |
| Ischemic stroke | $16,635.63 |
Notes and sources: (a) based on estimated monthly costs for average recommended dosages, extrapolated to represent annual costs; (b) ACE = angiotensin converting enzyme inhibitors, ARB = angiotensin receptor blockers; (c) MRA = mineralocorticoid receptor antagonist; (d) average of all CV non-HF hospitalization (6 month data); CV non-HF hospitalization include the following: Cardiac Arrhythmias/Cardiac Arrest, Hypotension/Syncope, Myocardial Infarction/Angina; (e) LVAD = left ventricular assist device; (f) two other BAT specific serious events [Prolonged Stay due to Dizziness; and Cranial Nerve Stimulation for Localized Neck Pain (341 days post implant)] occurred, but were not associated with any additional costs